This is a prospective, open-label, multicenter phase IV.II study. Patients with local relapse breast cancer will receive radiotherapy concomitant to the administration of capecitabine. Total dose of radiotherapy will be 50 Gy administered in daily session of 200 cGy. Radiotherapic treatment will not be longer than 6 weeks.